Ηνωμένο Βασίλειο - Αγγλικά - myHealthbox

midas pharma gmbh - ceftriaxone sodium - powder for solution for infusion - 2.38g - antibacterials for systemic use, third generation cephalosporins - it is indicated for the treatment of the following infections in adults and children including term neonates (from birth): • bacterial meningitis • community acquired pneumonia • hospital acquired pneumonia • acute otitis media • intra-abdominal infections • complicated urinary tract infections (including pyelonephritis) • infections of bones and joints • complicated skin and soft tissue infections • gonorrhoea • syphilis • bacterial endocarditis

Ηνωμένο Βασίλειο - Αγγλικά - myHealthbox

mip pharma gmbh - ceftazidime - powder for solution for injection/infusion - 1g - antibacterials for systemic use. third-generation cephalosporins - it is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). - nosocomial pneumonia - broncho-pulmonary infections in cystic fibrosis - bacterial meningitis - chronic suppurative otitis media - malignant otitis externa - complicated urinary tract infections - complicated skin and soft tissue infections - complicated intra-abdominal infections - bone and joint infections - peritonitis associated with dialysis in patients on capd

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;patients suffering from acute coronary syndrome:- non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:* patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

teva pharma b.v. - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.,

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

sandoz gmbh - pregabalin - anxiety disorders; epilepsy - antiepileptics, - epilepsypregabalin sandoz gmbh is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.generalised anxiety disorderpregabalin sandoz gmbh is indicated for the treatment of generalised anxiety disorder (gad) in adults.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

astellas pharma gmbh - tacrolimus - dermatitis, atopic - other dermatological preparations - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

Μάλτα - Αγγλικά - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - imatinib mesilate - film-coated tablet - imatinib mesilate 100 mg - antineoplastic agents

Μάλτα - Αγγλικά - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - imatinib mesilate - film-coated tablet - imatinib mesilate 400 mg - antineoplastic agents

Μάλτα - Αγγλικά - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - tadalafil - film-coated tablet - tadalafil 20 mg - urologicals